Clinical Trial Update: Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL) [Phase 3]

View source ↗

Summary

Phase 3 pivotal assessment for lubiprostone in opioid-induced bowel dysfunction completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Bowel Dysfunction

Drugs mentioned

• LUBIPROSTONE (lubiprostone)

Snippet

Sponsor: Sucampo Pharma Americas, LLC | Conditions: Opioid-induced Bowel Dysfunction | Phase 3 | Status: COMPLETED | Results posted: 2019-12-24